Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio Key International (BKYI) Cash & Equivalents (2016 - 2025)

Bio Key International's Cash & Equivalents history spans 16 years, with the latest figure at $2.0 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 13.25% year-over-year to $2.0 million; the TTM value through Sep 2025 reached $2.0 million, up 13.25%, while the annual FY2024 figure was $437604.0, 14.43% down from the prior year.
  • Cash & Equivalents for Q3 2025 was $2.0 million at Bio Key International, down from $2.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $13.5 million in Q1 2021 and bottomed at $307086.0 in Q3 2023.
  • The 5-year median for Cash & Equivalents is $2.3 million (2025), against an average of $3.8 million.
  • The largest annual shift saw Cash & Equivalents skyrocketed 1943.78% in 2021 before it crashed 88.93% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $7.8 million in 2021, then plummeted by 66.01% to $2.6 million in 2022, then crashed by 80.6% to $511400.0 in 2023, then fell by 14.43% to $437604.0 in 2024, then soared by 366.14% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for BKYI's Cash & Equivalents are $2.0 million (Q3 2025), $2.3 million (Q2 2025), and $3.1 million (Q1 2025).